- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.07. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson | 191 | GlobeNewswire (Europe) |
Former White House Council of Economic Advisors Brings Extensive Government, Academic, and Private Sector Experience to Advance Company's Strategic Growth JUPITER, FL, July 07, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 30.06. | JUPITER NEUROSCIENCES, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 26.06. | JUPITER NEUROSCIENCES, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 22.06. | JUPITER NEUROSCIENCES, INC. - 8-K, Current Report | - | SEC Filings | ||
| 05.06. | JUPITER NEUROSCIENCES, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 27.05. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson's Disease | 543 | GlobeNewswire (Europe) | Investigational Oral Candidate JOTROL Addresses a Parkinson's Disease Market with No Current Disease-modifying Therapies Available Jupiter, FL, May 27, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences... ► Artikel lesen | |
| 27.05. | Jupiter Neurosciences: EPS verfehlt Schätzungen - Umsatz schlechter als erwartet | 2 | Investing.com Deutsch | ||
| JUPITER NEUROSCIENCES Aktie jetzt für 0€ handeln | |||||
| 26.05. | D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. in Connection with its ~$2 Million Registered Direct Offering | 429 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / May 26, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS) ("Jupiter" or the "Company"), a clinical-stage biopharmaceutical company focused on central nervous system... ► Artikel lesen | |
| 21.05. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering | 5 | GlobeNewswire (USA) | ||
| 20.05. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering | 4 | GlobeNewswire (USA) | ||
| 20.05. | JUPITER NEUROSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million | 1 | GlobeNewswire (USA) | ||
| 20.05. | Jupiter Neurosciences, Inc.: Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech | 675 | GlobeNewswire (Europe) | Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May... ► Artikel lesen | |
| 14.05. | JUPITER NEUROSCIENCES, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.04. | Centri: Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14 | 507 | Newsfile | Jupiter, Florida--(Newsfile Corp. - April 13, 2026) - Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based platform... ► Artikel lesen | |
| 07.04. | Jupiter Neurosciences stärkt Beirat für Expansion im Consumer-Bereich | 4 | Investing.com Deutsch | ||
| 07.04. | Jupiter Neurosciences adds advisors for consumer product expansion | 1 | Investing.com | ||
| 07.04. | Jupiter Neurosciences verstärkt Beirat für Produktlinie Nugevia | 3 | Investing.com Deutsch | ||
| 07.04. | Jupiter Neurosciences adds advisors for consumer product line | 1 | Investing.com | ||
| 01.04. | JUPITER NEUROSCIENCES, INC. - 10-K, Annual Report | - | SEC Filings |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INNOCAN PHARMA | 1,650 | -8,84 % | INNOCAN PHARMA CORPORATION zeigt nachhaltige Stärke | ||
| TONIX PHARMACEUTICALS | 10,635 | +2,56 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA | New agreement, effective January 1, 2027, to add approximately 9 million Medicare lives (16% of approximately 55 million Medicare lives in the U.S.) On top of two previously announced major commercial... ► Artikel lesen | |
| JAGUAR HEALTH | 1,280 | -4,12 % | Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): Under Review | Original-Research: Jaguar Health Inc - from First Berlin Equity Research GmbH
17.07.2026 / 17:49 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer... ► Artikel lesen | |
| KALA BIO | 0,768 | -9,29 % | XFRA 27F: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILKALA BIO INC. O.N.... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 4,220 | +14,05 % | Galectin Therapeutics Inc.: Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension | Galectin has reached agreement with the FDA on the primary endpoint and regulatory path forward for the potential full approval of belapectinCompany intends to file the Phase 3 protocol in Q3 2026... ► Artikel lesen | |
| IRONWOOD PHARMACEUTICALS | 3,460 | +2,37 % | Ironwood Pharmaceuticals Names Jeffrey Silber Chief Medical Officer | ||
| GRACE THERAPEUTICS | 2,455 | +1,45 % | Grace Therapeutics, Inc.: Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update | Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 13,370 | +2,22 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 2,580 | +1,18 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium | Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual... ► Artikel lesen | |
| INMED PHARMACEUTICALS | 1,420 | +6,77 % | InMed Pharmaceuticals Inc. - 8-K, Current Report | ||
| MINDWALK | 1,230 | -0,81 % | MindWalk Holdings Corp. - 6-K, Report of foreign issuer | ||
| LIPOCINE | 2,250 | -1,75 % | Lipocine Inc.: Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 | SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment... ► Artikel lesen | |
| HERON THERAPEUTICS | 0,430 | +2,77 % | Heron Therapeutics, Inc.: U.S. District Court Issues Decision Regarding CINVANTI Patents | CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court... ► Artikel lesen | |
| HARROW | 38,200 | +7,30 % | Harrow, Inc.: Harrow Health, Inc. Announces Commercial Launch of BYOOVIZ in the United States | NASHVILLE, Tenn., July 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the commercial launch of... ► Artikel lesen | |
| INVENTIVA | 4,000 | +4,17 % | Cantor Fitzgerald initiates Inventiva stock with overweight rating |
Das Unternehmen JUPITER NEUROSCIENCES INC kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,78 % bei einem Aktienkurs von 0,171 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JUPITER NEUROSCIENCES INC finden Sie auf Wallstreet Online.